Navigation Links
New form of intravenous iron treats anemia in chronic kidney disease patients on dialysis
Date:1/27/2009

Ferumoxytol, a novel intravenous form of iron that permits rapid administration of large doses, has been shown to be effective for treating iron deficiency in chronic kidney disease (CKD) patients on dialysis, according to a clinical trial appearing in the February 2009 issue of the Clinical Journal of the American Society Nephrology (CJASN). The results indicate that this new agent may become an important treatment option for CKD patients.

Because blood is removed during dialysis, CKD patients undergoing this treatment often have anemia, or low red blood cell counts. These patients also are often iron deficient and must receive supplemental iron. While current treatment guidelines recommend intravenous iron for these patients, many clinicians believe that oral iron is much safer than intravenous iron, which has been associated with hypersensitivity reactions and low blood pressure. However, a new form of intravenous iron, ferumoxytol, may be a safe and effective alternative to other forms of iron therapy. Ferumoxytol appears to contain less free iron and be less immunogenic than other intravenous forms of iron.

Robert Provenzano, MD, FASN, of St. John Hospital and Medical Center in Detroit, MI, and his colleagues conducted a phase three clinical trial that compared ferumoxytol with oral iron. The trial enrolled 230 anemic patients with late stage CKD who were on dialysis. Patients received either two injections of 510 mg ferumoxytol within seven days or 200 mg oral iron daily for 21 days. The investigators measured the change in hemoglobin in patients from the start of the trial to day 35.

The two injections of ferumoxytol led to significantly greater hemoglobin increases compared with oral iron supplementation. Specifically, ferumoxytol caused an average of 1.02 g/dL increase in hemoglobin at day 35 compared with 0.46 g/dL with oral iron. Also, twice as many ferumoxytol-treated patients than oral irontreated patients achieved a ≥1 g/dL hemoglobin increase at day 35 (49.0% vs 25.0%). In addition, ferumoxytol was found to be well tolerated relative to oral iron, with 8.2% of ferumoxytol-treated subjects and 15.9% of oral iron-treated subjects experiencing adverse reactions considered by the investigator to be related to study treatment.

"Ferumoxytol administered as two rapid intravenous injections of 510 mg each within a week's time, led to significantly greater hemoglobin increases and was well tolerated as compared with oral iron," said Dr. Provenzano. He added that the study's findings also provide insight into factors that affect greater hemoglobin response to intravenous iron treatment, which makes ferumoxytol a potentially attractive treatment option for anemic hemodialysis patients."

AMAG Pharmaceuticals, Inc. funded the study, and its employees identified study sites, monitored the study to ensure adherence to Good Clinical Practice, and performed data analyses according to the predefined statistical analysis plan. Dr. Provenzano is a member of the Clinical Studies Steering Committee of AMAG Pharmaceuticals, Inc. Authors Brian Pereira, MD and Louis Brenner, MD are employees of AMAG Pharmaceuticals, Inc. Brigitte Schiller, MD and Daniel Coyne, MD were ferumoxytol study investigators. An abstract of some of these findings was submitted to the October 2007 ASN Meeting.


'/>"/>

Contact: Shari Leventhal
sleventhal@asn-online.org
202-416-0658
American Society of Nephrology
Source:Eurekalert

Related medicine news :

1. Most Important Factors Driving Usage of Antibiotics in the ICU Setting are Availability in Intravenous Formulation, Activity Against Key Gram Negative Pathogens, Drug Interactions and Bactericidal Activity
2. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
3. FDA Clears MDN-CGS(R) Intravenous Insulin Dosing Software
4. Lifeline Vascular Access Treats a Quarter Million Patients
5. Cancer drug effectively treats transplant rejections
6. Holiday Treats and Decorations Can Be a Deadly Combination for Pets
7. Slippery slope: 1 tiny truffle can trigger desire for more treats
8. Dogs Get Petty About Treats
9. Sealing off portion of intestinal lining treats obesity, resolves diabetes in animal model
10. Tips for Maintaining Your Physique While Enjoying Your Favorite Treats
11. Orthodontists Offer Sweet Incentives for Tricky Halloween Treats
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... ... Spine Team Texas, a comprehensive spine physician group specializing in the treatment ... been invited to be a featured speaker at the Texas Society of the American ... 2016. , Dr. R. Scott McPherson, a physical medicine and rehabilitation specialist, will ...
(Date:4/29/2016)... ... ... Mobility Designed is redefining mobility with their patent pending crutch design. ... distributes body weight from the elbow to the forearm. In consumer tests, users ... other crutches. , Co-founders Max and Liliana Younger were inspired to design the crutches ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Gluten-Free ... is pleased to announce the launch of the GFCP Scoop in ... more. The purpose of the GFCP Scoop site is to keep ...
(Date:4/29/2016)... ... ... Dr. Robert Mondavi, one of the dentists in Torrance , is now ... as more patients are discovering the many different ways they can change and improve ... to them and which ones might work for their smiles. , “One of ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly announces ... the head and neck/ear, nose and throat specialty, has added the KOTLER NASAL AIRWAY™ ... NASAL AIRWAY™ is a newly patented safety device secured by nasal surgeons onto ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016  ValGenesis, Inc., the market ... (VLMS) today announced that a prominent world ... of chronic kidney failure has selected ValGenesis ... corporate validation process. The global medical device ... to manage their validation processes electronically. Upon ...
(Date:4/27/2016)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... second quarter ended March 26, 2016.  GAAP diluted ... and non-GAAP diluted EPS of $0.47 increased 14.6%.  ... reported basis, and 6.3% on a constant currency ... quarter, highlighted by 14.6% growth in non-GAAP EPS," ...
(Date:4/27/2016)... 2016   , ... Recurring Consumable Sales  Clinical sales grow 16% ... (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... the first quarter ended March 31, 2016 and provided ... its commercial strategy. First Quarter 2016 Revenue ...
Breaking Medicine Technology: